2025-10-11 - Analysis Report
Okay, here's an analysis of Merck & Co Inc (MRK) based on the data you provided, presented in English with a focus on key metrics and insights:

## Merck & Co Inc (MRK) Analysis

**Company Overview:** Merck & Co Inc is a global pharmaceutical company that develops and provides health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products.

**1. Performance vs. S&P 500 (VOO)**

*   **MRK Cumulative Return:** 2.34%
*   **VOO Cumulative Return:** 99.08%
*   **Absolute Divergence:** -97.5
*   **Relative Divergence:** 5.0 (meaning the current divergence is near the lower end of its historical range compared to VOO)

**Analysis:** MRK has significantly underperformed the S&P 500 over the period examined. The relative divergence suggests that this underperformance is near its historical worst compared to the benchmark.

**Alpha/Beta Analysis:**

| Year       | CAGR   | MDD     | Alpha    | Beta   | Cap(B) |
|------------|--------|---------|----------|--------|--------|
| 2015-2017  | 1.0%   | 68.5%   | -28.0%   | 0.0    | 134.1  |
| 2016-2018  | 36.0%  | 69.8%   | 21.0%    | -0.0   | 182.1  |
| 2017-2019  | 40.0%  | 69.8%   | 18.0%    | 0.3    | 216.7  |
| 2018-2020  | 16.0%  | 79.6%   | -8.0%    | 0.3    | 194.9  |
| 2019-2021  | 2.0%   | 79.6%   | -44.0%   | 0.7    | 191.4  |
| 2020-2022  | 15.0%  | 79.6%   | 16.0%    | 0.7    | 277.1  |
| 2021-2023  | 33.0%  | 79.6%   | 31.0%    | 0.3    | 272.3  |
| 2022-2024  | -4.0%  | 79.6%   | -25.0%   | 0.2    | 248.4  |
| 2023-2025  | -47.0% | 71.5%   | -111.0%  | 1.5    | 216.2  |

**Analysis:**

*   **CAGR:** Fluctuating CAGR, with a recent significant drop to -47% (2023-2025).
*   **MDD:** Consistently high Maximum Drawdown, indicating significant volatility and potential for losses.
*   **Alpha:** Inconsistent alpha, with recent years showing significantly negative values. This suggests underperformance relative to the market on a risk-adjusted basis.
*   **Beta:** Beta values are generally low, indicating lower sensitivity to market movements than the S&P 500. However, the Beta has increased drastically recently, implying that the recent stock performance has been highly correlated to the index.
*   **Cap:** Market capitalization has fluctuated over the years.

**2. Recent Stock Price Movements**

*   **Current Price:** 86.555
*   **Last Market Data:** Price: 86.57, Previous Close: 87.5, Change: -1.06
*   **5-Day Moving Average:** 87.711
*   **20-Day Moving Average:** 83.372
*   **60-Day Moving Average:** 83.0679

**Analysis:**

*   The stock price closed slightly lower than the previous day.
*   The current price is below the 5-day moving average but above the 20-day and 60-day moving averages. This suggests a possible short-term downward trend, but still above the longer-term trend.

**3. Technical Indicators**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 62.41 (Neither overbought nor oversold)
*   **PPO:** 0.6778 (Positive, indicating a potential upward trend)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (35 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-10-01)
*   **Delta_Previous_Relative_Divergence:** -4.5 (Negative, indicating recent underperformance)
*   **Expected Return:** -126.1% (Significant underperformance expected compared to S&P 500 over a 2+ year investment horizon)
*   **Last-market issue:** The change of -1.06 indicates a recent downward fluctuation, though not extreme.

**Analysis:**

*   The MRI suggests that from the perspective of Market Risk, MRK is a good recommendation.
*   The RSI is in a neutral zone.
*   The PPO suggests a potential upward trend.
*   However, the recent decrease in stock price and a negative "Delta_Previous_Relative_Divergence" indicate possible downward momentum.
*   Most concerning is the very negative "Expected Return," suggesting a bleak long-term outlook compared to the S&P 500.

**4. Recent News & Significant Events (Yahoo Finance)**

*   **Keytruda's Impact on Q3 Earnings:** Focus on the continued contribution of Keytruda to Merck's revenue.
*   **Analyst Price Target Adjustment:** Goldman Sachs adjusted the price target to $93 (Buy Rating).
*   **Oncology Innovation:** Merck is presenting data on advancements in oncology, including new tumor types and earlier stages of disease.
*   **HIV Treatment and Prevention:** Merck is presenting data from its HIV pipeline.

**Analysis:**

*   The news is mixed. Keytruda remains a focus, and analyst price targets (while reduced slightly) still suggest upside.
*   The focus on oncology and HIV pipelines suggests potential future growth areas.

**4-2. Analyst Opinions**

*   **Consensus:** Buy
*   **Mean Rating:** 2.00 (Buy)
*   **Number of Opinions:** 25
*   **Target Price (Avg/High/Low):** 101.40 / 137.00 / 82.00

**Analysis:**

*   The analyst consensus is generally positive, with a "Buy" rating and an average target price significantly above the current price. However, the range of target prices is wide, indicating uncertainty.

**5. Recent Earnings Analysis**

| Date       | EPS   | Revenue      |
|------------|-------|--------------|
| 2025-08-05 | 1.76  | 15.81 B$     |
| 2025-05-02 | 2.01  | 15.53 B$     |
| 2024-11-06 | 1.25  | 16.66 B$     |
| 2024-08-05 | 2.15  | 16.11 B$     |
| 2025-08-05 | 2.15  | 16.11 B$     |

**Analysis:**

*   Revenue has fluctuated, with some recent declines.
*   EPS has also varied.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-06-30   | $15.81B   | 77.50%        |
| 2025-03-31   | $15.53B   | 77.98%        |
| 2024-12-31   | $15.62B   | 75.50%        |
| 2024-09-30   | $16.66B   | 75.51%        |
| 2024-06-30   | $16.11B   | 76.76%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE     |
|--------------|-----------|---------|
| 2025-06-30   | $48.99B   | 9.04%   |
| 2025-03-31   | $48.34B   | 10.51%  |
| 2024-12-31   | $46.31B   | 8.08%   |
| 2024-09-30   | $44.50B   | 7.09%   |
| 2024-06-30   | $43.58B   | 12.52%  |

**Analysis:**

*   Revenue has been relatively stable.
*   Profit margins are strong.
*   Equity has been growing.
*   ROE has fluctuated, indicating variability in profitability relative to equity.

**7. Overall Analysis**

*   **Underperformance:** MRK has significantly underperformed the S&P 500.
*   **Mixed Technicals:** Technical indicators are mixed. The MRI and analyst ratings are positive but the RSI, "Delta_Previous_Relative_Divergence" and the negative "Expected Return" raise concern.
*   **Earnings and Financials:** Earnings and revenue have fluctuated, but profit margins remain strong and the company's equity is growing.
*   **Analyst Sentiment:** Analysts are generally positive but there may be a lot of uncertainty, evident from the high distribution of target prices.
*   **News:** News is mixed with positive points about new drugs as well as lowered price targets.

**Conclusion:**

MRK presents a mixed picture. While analysts are largely positive and the company has strong financials, the significant underperformance relative to the S&P 500 and concerning technical indicators such as the negative expected return warrant caution. Recent news regarding drug developments are also positive signals, but the big picture indicates some amount of risk.
